stockrowNeoGenomics, Inc. (NEO) vs Veracyte, Inc. (VCYT)
- NeoGenomics, Inc. NEO 16.89 +2.43%
- Veracyte, Inc. VCYT 24.14 +0.58%
NeoGenomics, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.1B against $1.9B — 1.1× the size. NeoGenomics, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 15.2×. Veracyte, Inc. grew revenue faster over the last twelve months: 17.5% against 11.1%. Veracyte, Inc. has the higher net margin (21.8% vs −4.10%) and the higher return on invested capital (5.85% vs −2.97%). Across the 19 metrics below, Veracyte, Inc. leads on 18 and NeoGenomics, Inc. on 1.
Valuation
Profitability
| Metric | NEO | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 44.77% | 71.98% | 48.32% |
| Operating margin | (6.27%) | 17.08% | (5.68%) |
| Net margin | (4.10%) | 21.80% | (4.10%) |
| Free cash flow margin | (3.37%) | 27.84% | 0.00% |
| Return on equity | (3.94%) | 9.43% | 0.00% |
| Return on assets | (2.35%) | 8.63% | (6.05%) |
| Return on invested capital | (2.97%) | 5.85% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack